Sanofi reports positive PhIII data on oral Gaucher drug

Sanofi ($SNY) reported positive data from two late-stage studies for a new oral therapy for Gaucher disease. Current therapies for Gaucher rely on an injected enzyme replacement approach, but Sanofi's oral strategy for eliglustat could seriously undercut those drugs. Only some 10,000 people in the U.S. have this rare disease. But they pay 6 figures for their drugs, making this treatment potentially worth around $360 million a year for Sanofi, according to Thomson Reuters. Story


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.